{"transactions":[{"id":4623715,"issuer":{"id":9265,"kind":"organization","name":"Electra Therapeutics, Inc.","symbol":"ETRA"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2026-09-21T22:19:01.000Z","date":"2026-09-21","kind":"exercise","planned":false,"acquired":false,"shares":255635,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":255635},"source":{"system":"sec-edgar","filing":"0001817449-26-000009","document":"form4-09212026_100957.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2088082/000181744926000009/form4-09212026_100957.xml","form_type":"4"}},{"id":4623714,"issuer":{"id":9265,"kind":"organization","name":"Electra Therapeutics, Inc.","symbol":"ETRA"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-21T22:19:01.000Z","date":"2026-09-21","kind":"exercise","planned":false,"acquired":true,"shares":255635,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A Convertible Preferred Stock (the \"Preferred Stock\") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date."}],"balance_after":255635,"source":{"system":"sec-edgar","filing":"0001817449-26-000009","document":"form4-09212026_100957.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2088082/000181744926000009/form4-09212026_100957.xml","form_type":"4"}},{"id":2764558,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-04-01T19:46:19.000Z","date":"2021-04-01","kind":"disposition_to_issuer","acquired":false,"shares":17671,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All options were vested and exercisable as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":17671},"source":{"system":"sec-edgar","filing":"0000899243-21-014447","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924321014447/doc4.xml","form_type":"4"}},{"id":2764557,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:46:19.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":73067,"price":60,"value":4384020.0,"ownership":{"direct":false,"nature":"By The Nancy E. Stagliano Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924321014447/doc4.xml","form_type":"4"}},{"id":2764556,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T19:46:19.000Z","date":"2021-04-01","kind":"other","acquired":false,"shares":1000,"price":60,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the \"Company\"), Merck Sharp & Dohme Corp. (\"Merck\") and Panama Merger Sub, Inc. (\"Merger Sub\"), Merger Sub commenced a tender offer (the \"Offer\") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the \"Offer Price\"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the \"Merger\") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the \"Effective Time\"), were cancelled and converted automatically into the right to receive the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014447","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924321014447/doc4.xml","form_type":"4"}},{"id":3078981,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":47898,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Nancy E. Stagliano Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9392},"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}},{"id":3078980,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":28620,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Nancy E. Stagliano Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5612},"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}},{"id":3078979,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":13997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option award was granted on July 17, 2020. The shares underlying the award vest in equal monthly installments following July 17, 2020 through July 17, 2023, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":13997,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":13997},"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}},{"id":3078978,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":3674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option award was granted on July 17, 2020. The shares underlying the award vest in equal quarterly installments following June 28, 2018 through June 28, 2022, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":3674,"derivative":{"exercise_price":18,"expiration_date":"2030-07-16","underlying":"Common Stock","underlying_shares":3674},"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}},{"id":3078977,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":1000,"price":18,"value":18000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}},{"id":3078976,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":140699,"kind":"person","name":"Stagliano Nancy","position":1,"cik":"0001817449","reported_name":"Stagliano Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-07-21T19:33:05.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":15004,"ownership":{"direct":false,"nature":"By The Nancy E. Stagliano Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":73067,"source":{"system":"sec-edgar","filing":"0000899243-20-019863","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817449/000089924320019863/doc4.xml","form_type":"4"}}]}